Managing Dysregulated Vitamin D Metabolism in CKD: Time to Update Conventional Wisdom? - PubMed (original) (raw)

Managing Dysregulated Vitamin D Metabolism in CKD: Time to Update Conventional Wisdom?

Charles W Bishop et al. Kidney360. 2025.

No abstract available

Keywords: CKD; CKD-MBD; clinical trial; dialysis; metabolism; nephrology; parathyroid hormone; renal progression; vitamin D.

PubMed Disclaimer

Conflict of interest statement

Disclosure forms, as provided by each author, are available with the online version of the article at http://links.lww.com/KN9/B268.

Figures

Figure 1

Figure 1

Proposed update to current treatment paradigm for dysregulated vitamin D metabolism in CKD. Extrarenal expression of CYP27B1 occurs in skin, parathyroids, lungs, bone, and immune cells (as depicted) and in many other tissues. 1,25D, 1,25-dihydroxyvitamin D; 25D, 25-hydroxyvitamin D; Ca, calcium; CYP24, cytochrome P450 24-hydroxylase; CYP27A1, cytochrome P450 25-hydroxylase; CYP27B1, cytochrome P450 25D-1_α_-hydroxylase; FGF23, fibroblast growth factor 23; P, phosphorus; PTH, parathyroid hormone.

References

    1. Kidney Disease Improving Global Outcomes (KDIGO) CKD-MBD Update Work Group. KDIGO 2017 clinical practice guideline update for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease: mineral and bone disorder. Kidney Int Suppl. 2017;7(1):1–59. doi: 10.1016/j.kisu.2017.04.001 -DOI
    1. Bishop CW, Strugnell SA, Csomor P, Kaiser E, Ashfaq A. Extended-release calcifediol effectively raises serum total 25-hydroxyvitamin D even in overweight non-dialysis chronic kidney disease patients with secondary hyperparathyroidism. Am J Nephrol. 2022;53(6):446–454. doi: 10.1159/000524289 -DOI -PMC -PubMed
    1. Ashfaq A Choe J Strugnell SA, et al. Adjunctive active vitamin D decreases kidney function during treatment of secondary hyperparathyroidism with extended-release calcifediol in non-dialysis chronic kidney disease in a randomized trial. Am J Nephrol. 2025;56(4):490–499. doi: 10.1159/000544086 -DOI -PMC -PubMed
    1. Bishop CW Ashfaq A Choe J, et al. Extended-release calcifediol normalized 1,25-Dihydroxyvitamin D and prevented progression of secondary hyperparathyroidism in hemodialysis patients in a pilot randomized clinical trial. Am J Nephrol. 2025:1–11. doi: 10.1159/000546615 -DOI
    1. Strugnell SA, Sprague SM, Ashfaq A, Petkovich M, Bishop CW. Rationale for raising current clinical practice guideline target for serum 25-hydroxyvitamin D in chronic kidney disease. Am J Nephrol. 2019;49(4):284–293. doi: 10.1159/000499187 -DOI -PubMed

LinkOut - more resources